Results for the First Quarter 2024

Posted on
by Medistim

Sales ended at MNOK 133.8, 3.5% above first quarter last year (MNOK 129.3). Currency neutral sales of own products was down 1%. Recurring sales remain high at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter. Strong quarter for the direct sales operations in Europe and EMEA delivers 32% currency neutral growth while growth in AMERICAS and APAC was influenced by strong comparables from Q1 last year. Operating profit (EBIT) for the quarter ended at MNOK 32.1 giving a 24.0% EBIT margin (MNOK 33.5, a 25.9% margin).

Read full report and presentation on Medistim's Financial Presentations page.